A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus

Abstract The safety profiles of sodium-glucose co-transporter 2 (SGLT2) inhibitors may depend on races/ethnicities. We aimed to assess the safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus (DM). The electronic databases MEDLINE, CENTRAL, and Ichushi-web were searched fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Junichi Mukai, Shinya Kanno, Rie Kubota
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1e7064ff382040a3b39585d79974b8b1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e7064ff382040a3b39585d79974b8b1
record_format	dspace
spelling	oai:doaj.org-article:1e7064ff382040a3b39585d79974b8b12021-12-02T16:10:38ZA literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus10.1038/s41598-021-92925-22045-2322https://doaj.org/article/1e7064ff382040a3b39585d79974b8b12021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92925-2https://doaj.org/toc/2045-2322Abstract The safety profiles of sodium-glucose co-transporter 2 (SGLT2) inhibitors may depend on races/ethnicities. We aimed to assess the safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus (DM). The electronic databases MEDLINE, CENTRAL, and Ichushi-web were searched for studies with no language restriction from their inception to August 2019. Trials were included in the analysis if they were randomized controlled trials (RCTs) comparing the effects of SGLT2 inhibitors with a placebo in Japanese patients with DM > 18 years and reporting HbA1c and at least 1 adverse event. We calculated risk ratios with 95% CIs and used a random-effects model. Of the 22 RCTs included in our review, only 1 included patients with type 1 DM. The durations of RCTs ranged between 4 and 24 weeks. In comparison with a placebo, SGLT2 inhibitors were associated with similar risks of hypoglycemia, urinary tract infection, genital infection, hypovolemia, and fracture. The outcomes of treatment with SGLT2 inhibitors among Japanese patients with DM suggest favorable safety profiles. However, further evidence from studies with a longer duration, involving more diverse populations, such as patients with different types of DM, or including individual SGLT2 inhibitors is needed to resolve the limitations of the present study.Junichi MukaiShinya KannoRie KubotaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Junichi Mukai Shinya Kanno Rie Kubota A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
description	Abstract The safety profiles of sodium-glucose co-transporter 2 (SGLT2) inhibitors may depend on races/ethnicities. We aimed to assess the safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus (DM). The electronic databases MEDLINE, CENTRAL, and Ichushi-web were searched for studies with no language restriction from their inception to August 2019. Trials were included in the analysis if they were randomized controlled trials (RCTs) comparing the effects of SGLT2 inhibitors with a placebo in Japanese patients with DM > 18 years and reporting HbA1c and at least 1 adverse event. We calculated risk ratios with 95% CIs and used a random-effects model. Of the 22 RCTs included in our review, only 1 included patients with type 1 DM. The durations of RCTs ranged between 4 and 24 weeks. In comparison with a placebo, SGLT2 inhibitors were associated with similar risks of hypoglycemia, urinary tract infection, genital infection, hypovolemia, and fracture. The outcomes of treatment with SGLT2 inhibitors among Japanese patients with DM suggest favorable safety profiles. However, further evidence from studies with a longer duration, involving more diverse populations, such as patients with different types of DM, or including individual SGLT2 inhibitors is needed to resolve the limitations of the present study.
format	article
author	Junichi Mukai Shinya Kanno Rie Kubota
author_facet	Junichi Mukai Shinya Kanno Rie Kubota
author_sort	Junichi Mukai
title	A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
title_short	A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
title_full	A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
title_fullStr	A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
title_full_unstemmed	A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
title_sort	literature review and meta-analysis of safety profiles of sglt2 inhibitors in japanese patients with diabetes mellitus
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1e7064ff382040a3b39585d79974b8b1
work_keys_str_mv	AT junichimukai aliteraturereviewandmetaanalysisofsafetyprofilesofsglt2inhibitorsinjapanesepatientswithdiabetesmellitus AT shinyakanno aliteraturereviewandmetaanalysisofsafetyprofilesofsglt2inhibitorsinjapanesepatientswithdiabetesmellitus AT riekubota aliteraturereviewandmetaanalysisofsafetyprofilesofsglt2inhibitorsinjapanesepatientswithdiabetesmellitus AT junichimukai literaturereviewandmetaanalysisofsafetyprofilesofsglt2inhibitorsinjapanesepatientswithdiabetesmellitus AT shinyakanno literaturereviewandmetaanalysisofsafetyprofilesofsglt2inhibitorsinjapanesepatientswithdiabetesmellitus AT riekubota literaturereviewandmetaanalysisofsafetyprofilesofsglt2inhibitorsinjapanesepatientswithdiabetesmellitus
_version_	1718384395054743552

A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus

Ejemplares similares